E-GEOD-51020 - Gene expression profiling of MYC-amplified medulloblastoma cell lines treated by JQ1, a BET bromodomain inhibitor

Status
Released on 2 December 2013, last updated on 9 December 2013
Organism
Homo sapiens
Samples (10)
Array (1)
Protocols (7)
Description
MYC-amplified medulloblastomas are highly lethal tumors. BET bromodomain inhibition was recently described to downregulate MYC-associated transcriptional activity in various cancer subtypes. To investigate whether JQ1, a BET bromodomain inhibitor is downregulation MYC and MYC-associated transcriptional activity, we performed global gene expression profiling of five medulloblastomas MYC-amplified patient-derived cell lines treated by JQ1 and the inactive form of JQ1. Five medulloblastomas patient-derived MYC-amplified cell lines were treated with the active and the inactive form of the drug (JQ1S or JQ1R, respectively, 1μM for 24 hours) followed by RNA extraction and hybridization on Affymetrix microarrays
Experiment type
transcription profiling by array 
Contacts
MIAME
PlatformsProtocolsVariablesProcessedRaw
Files
Investigation descriptionE-GEOD-51020.idf.txt
Sample and data relationshipE-GEOD-51020.sdrf.txt
Raw data (1)E-GEOD-51020.raw.1.zip
Processed data (1)E-GEOD-51020.processed.1.zip
Array designA-AFFY-141.adf.txt
Links